Myovant's Drug To Treat Uterine Fibroids Hits Key Goals In Phase III Study

Myovant Sciences' (MYOV) phase III study of once daily Relugolix combination therapy met its primary and key secondary goals in women with uterine fibroids and heavy menstrual bleeding.

from RTT - Biotech http://bit.ly/2VBRtJ9
via IFTTT